Drugs

Medivation Exercises License Option for Pidilizumab

SAN FRANCISCO, CA and YAVNE, ISRAEL: ...

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics

BOTHELL, WA and SAN DIEGO, CA: MiNA Therapeutics to Develop Therapeutics Utilizing Proprietary saRNA Compounds Combined With Marina's Novel SMARTICLES(R) Delivery Technology ...

Knight Further Executes Its Innovative Pharmaceutical Product Sourcing Strategy

MONTREAL, QUEBEC: ...

Merus Labs International Inc. Appoints Barry Fishman as Chief Executive Officer

TORONTO, ONTARIO: ...

VANC Pharmaceuticals Announces Drug Establishment License Issued by Health Canada

VANCOUVER, BRITISH COLUMBIA: ...

Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014

BOTHELL, WA: SMARTICLES(R) Formulated PNT2258 Achieved Meaningful Therapeutic Outcomes ...

Kadmon Corporation Presents Preclinical Data on KD025 in Chronic Graft-Versus-Host-Disease at American Society of Hematology Annual Meeting

SAN FRANCISCO, CA: KD025 a Potential Novel Therapeutic Approach to Treating Chronic GVHD ...

Global Blood Therapeutics'' GBT440 Demonstrates Ability to Positively Impact Fundamental Sickle Cell Disease (SCD) Processes in Studies Presented at 2014 American Society of Hematology (ASH) Conference

SOUTH SAN FRANCISCO, CA: Groundbreaking Chronic Prophylactic Treatment for SCD Is Focus of Oral and Poster Presentations, Data Paves Way for Advancing GBT440 Into Clinical Studies ...

NeutriSci Engages Investor Relations Firm and Confirms Trading Date

VANCOUVER, BRITISH COLUMBIA: ...

Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement

MONTREAL, CANADA: ...